alpha-Helix mimetics as inhibitors of protein-protein interactions.

The inhibition of protein-protein interactions using small molecules is a viable approach for the treatment of a range of pathological conditions that result from a malfunctioning of these interactions. Our strategy for the design of such agents involves the mimicry of side-chain residues on one face of the alpha-helix; these residues frequently play a key role in mediating protein-protein interactions. The first-generation terphenyl scaffold, with a 3,2',2''-substitution pattern, is able to successfully mimic key helix residues and disrupt therapeutically relevant interactions, including the Bcl-X(L)-Bak and the p53-hDM2 (human double minute 2) interactions that are implicated in cancer. The second- and third-generation scaffolds have resulted in greater synthetic accessibility and more drug-like character in these molecules.

[1]  Jorge Becerril,et al.  Design and application of an alpha-helix-mimetic scaffold based on an oligoamide-foldamer strategy: antagonism of the Bak BH3/Bcl-xL complex. , 2003, Angewandte Chemie.

[2]  D. Hoyer,et al.  Design and synthesis of gamma-dipeptide derivatives with submicromolar affinities for human somatostatin receptors. , 2003, Angewandte Chemie.

[3]  P. Toogood.  Inhibition of protein-protein association by small molecules: approaches and progress. , 2002, Journal of medicinal chemistry.

[4]  A. Hamilton,et al.  Helix mimetics as inhibitors of the interaction of the estrogen receptor with coactivator peptides. , 2007, Angewandte Chemie.

[5]  Daniel A Erlanson,et al.  Tethering: fragment-based drug discovery. , 2004, Annual review of biophysics and biomolecular structure.

[6]  A. Hamilton,et al.  Toward proteomimetics: terphenyl derivatives as structural and functional mimics of extended regions of an alpha-helix. , 2001, Journal of the American Chemical Society.

[7]  Andrew D. Hamilton,et al.  Terphenyl-Based Bak BH3 α-Helical Proteomimetics as Low-Molecular-Weight Antagonists of Bcl-xL , 2005 .

[8]  Andrew D. Hamilton,et al.  Development of a Potent Bcl-xL Antagonist Based on α-Helix Mimicry , 2002 .

[9]  A. Schepartz,et al.  Molecular recognition of protein surfaces: high affinity ligands for the CBP KIX domain. , 2003, Journal of the American Chemical Society.

[10]  Michelle R Arkin,et al.  Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. , 2003, Journal of the American Chemical Society.

[11]  S. Sebti,et al.  Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction. , 2005, Angewandte Chemie.

[12]  A. Hamilton,et al.  Intramolecular hydrogen bonding allows simple enaminones to structurally mimic the i, i + 4, and i + 7 residues of an α-helix , 2006 .

[13]  Michael S. Kay,et al.  Inhibiting HIV Fusion with a β-Peptide Foldamer , 2005 .

[14]  C. J. Knill,et al.  Foldamers: Structure, Properties, and Applications, S. Hecht, I. Huc (Eds.). Wiley-VCH, Weinheim, Germany (2007), , 434 pp., £159.00, ISBN: 3-527-31563-5 , 2008 .

[15]  A. Hamilton,et al.  Strategies for targeting protein-protein interactions with synthetic agents. , 2005, Angewandte Chemie.

[16]  Michelle R. Arkin,et al.  Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.

[17]  T. Satoh,et al.  A computer screening approach to immunoglobulin superfamily structures and interactions: discovery of small non-peptidic CD4 inhibitors as novel immunotherapeutics. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[19]  S. Sebti,et al.  Terephthalamide derivatives as mimetics of helical peptides: disruption of the Bcl-x(L)/Bak interaction. , 2005, Journal of the American Chemical Society.

[20]  D. Coppola,et al.  Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice , 2000, Nature Biotechnology.

[21]  A. Debnath,et al.  Design of a Protein Surface Antagonist Based on α-Helix Mimicry: Inhibition of gp41 Assembly and Viral Fusion We thank the National Institutes of Health for support of this work and the Deutsche Forschungsgemeinschaft (DFG) for a research fellowship to O.K. , 2002 .

[22]  S. Matile,et al.  Artificial beta-barrels. , 2008, Accounts of chemical research.

[23]  L. Stockwin,et al.  Antibodies as therapeutic agents: vive la renaissance! , 2003, Expert opinion on biological therapy.

[24]  W Seth Horne,et al.  Sequence-based design of alpha/beta-peptide foldamers that mimic BH3 domains. , 2008, Angewandte Chemie.

[25]  A. Hamilton,et al.  Protein surface recognition by synthetic receptors based on a tetraphenylporphyrin scaffold. , 2000, Organic letters.

[26]  A. Hamilton,et al.  Diphenylindane-based proteomimetics reproduce the projection of the i, i+3, i+4, and i+7 residues on an alpha-helix. , 2006, Organic letters.

[27]  J. Chmielewski,et al.  Scaffolds for blocking protein-protein interactions. , 2007, Current topics in medicinal chemistry.

[28]  S. Mann.  Biomineralization: Principles and Concepts in Bioinorganic Materials Chemistry , 2002 .

[29]  A. Hamilton,et al.  Design of a synthetic foldamer that modifies the growth of calcite crystals. , 2004, Journal of the American Chemical Society.

[30]  W. Stites,et al.  Protein−Protein Interactions: Interface Structure, Binding Thermodynamics, and Mutational Analysis , 1997 .

[31]  T. Clackson,et al.  A hot spot of binding energy in a hormone-receptor interface , 1995, Science.

[32]  Andrew D. Hamilton,et al.  Synthesis of a 2,3‘;6‘,3‘ ‘-Terpyridine Scaffold as an α-Helix Mimetic , 2005 .

[33]  Andrew D. Hamilton,et al.  Benzoylurea Oligomers: Synthetic Foldamers That Mimic Extended α Helices , 2007 .

[34]  S. Gellman,et al.  Targeting protein-protein interactions: lessons from p53/MDM2. , 2007, Biopolymers.